These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 31152476

  • 21. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
    Lin M, Mittal S, Sahebjam F, Rana A, Sood GK.
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
    [Abstract] [Full Text] [Related]

  • 22. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
    Budde K, Zeier M, Witzke O, Arns W, Lehner F, Guba M, Jacobi J, Kliem V, Reinke P, Hauser IA, Vogt B, Stahl R, Rath T, Duerr M, Paulus EM, May C, Porstner M, Sommerer C, HERAKLES Study Group.
    Nephrol Dial Transplant; 2017 Jun 01; 32(6):1060-1070. PubMed ID: 28605781
    [Abstract] [Full Text] [Related]

  • 23. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
    Cillo U, Saracino L, Vitale A, Bertacco A, Salizzoni M, Lupo F, Colledan M, Corno V, Rossi G, Reggiani P, Baccarani U, Bresàdola V, De Carlis L, Mangoni I, Ramirez Morales R, Agnes S, Nure E.
    Liver Transpl; 2019 Feb 01; 25(2):242-251. PubMed ID: 30592371
    [Abstract] [Full Text] [Related]

  • 24. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
    Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, Schemmer P, Fischer L, Klein CG, Nadalin S, Lehner F, Settmacher U, Gotthardt D, Loss M, Ladenburger S, Wimmer P, Dworak M, Schlitt HJ.
    Clin Transplant; 2016 Jun 01; 30(6):741-8. PubMed ID: 27160359
    [Abstract] [Full Text] [Related]

  • 25. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar 01; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 26. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E, Juinier E, Guidicelli G, Dromer C, Merville P, Billes MA, Taupin JL, Neau-Cransac M.
    Clin Transplant; 2014 Sep 01; 28(9):1054-60. PubMed ID: 25040585
    [Abstract] [Full Text] [Related]

  • 27. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B, Tönshoff B.
    Paediatr Drugs; 2011 Feb 01; 13(1):49-69. PubMed ID: 21162600
    [Abstract] [Full Text] [Related]

  • 28. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov 01; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 29. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.
    De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S, Sudan D, Fung J, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Witte S, Jiang H, Hexham JM, Junge G, H2304 Study Group.
    Am J Transplant; 2012 Nov 01; 12(11):3008-20. PubMed ID: 22882750
    [Abstract] [Full Text] [Related]

  • 30. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
    Budde K, Rath T, Sommerer C, Haller H, Reinke P, Witzke O, Suwelack B, Baeumer D, May C, Porstner M, Arns W.
    Clin Nephrol; 2015 Jan 01; 83(1):11-21. PubMed ID: 25512099
    [Abstract] [Full Text] [Related]

  • 31. A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).
    Manzia TM, Carmellini M, Todeschini P, Secchi A, Sandrini S, Minetti E, Furian L, Spagnoletti G, Pisani F, Piredda GB, Cappelli G, Tisone G.
    Transplantation; 2020 Feb 01; 104(2):374-386. PubMed ID: 31335776
    [Abstract] [Full Text] [Related]

  • 32. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B, Schemmer P, Braun F, Dworak M, Wimmer P, Schlitt H.
    Trials; 2015 Mar 26; 16():118. PubMed ID: 25873064
    [Abstract] [Full Text] [Related]

  • 33. Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.
    Höcker B, Zencke S, Pape L, Krupka K, Köster L, Fichtner A, Dello Strologo L, Guzzo I, Topaloglu R, Kranz B, König J, Bald M, Webb NJ, Noyan A, Dursun H, Marks S, Ozcakar ZB, Thiel F, Billing H, Pohl M, Fehrenbach H, Schnitzler P, Bruckner T, Ahlenstiel-Grunow T, Tönshoff B.
    Am J Transplant; 2016 Mar 26; 16(3):921-9. PubMed ID: 26613840
    [Abstract] [Full Text] [Related]

  • 34. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators.
    Lancet; 2011 Mar 05; 377(9768):837-47. PubMed ID: 21334736
    [Abstract] [Full Text] [Related]

  • 35. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Duvoux C, Nevens F, Fung JJ, Dong G, Rauer B, Junge G, H2304 Study Group.
    Transplantation; 2015 Jul 05; 99(7):1455-62. PubMed ID: 26151607
    [Abstract] [Full Text] [Related]

  • 36. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.
    Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, Schemmer P, Fischer L, Klein CG, Nadalin S, Lehner F, Settmacher U, Neuhaus P, Gotthardt D, Loss M, Ladenburger S, Paulus EM, Mertens M, Schlitt HJ.
    Am J Transplant; 2014 Mar 05; 14(3):701-10. PubMed ID: 24502384
    [Abstract] [Full Text] [Related]

  • 37. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
    Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, Wüthrich RP, Mühlfeld A, Heller K, Porstner M, Veit J, Paulus EM, Witzke O, ZEUS Study Investigators.
    Am J Transplant; 2015 Jan 05; 15(1):119-28. PubMed ID: 25521535
    [Abstract] [Full Text] [Related]

  • 38. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec 05; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 39. Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial.
    Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters-Sengers H, de Maar EF, van der Pant KA, de Vries AP, Sanders JS, Zwinderman A, Idu MM, Berger S, Reinders ME, Krikke C, Bajema IM, van Dijk MC, Ten Berge IJ, Ringers J, Lardy J, Roelen D, Moes DJ, Florquin S, Homan van der Heide JJ.
    Am J Transplant; 2017 Apr 05; 17(4):1020-1030. PubMed ID: 27639190
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.